Krystal Biotech, Inc. Q4 2025 Earnings Call Summary

Management attributed Q4 performance to successful US sales force expansion and initial revenue contributions from early launches in Germany, France, and Japan. The US market is evolving toward a 'start-stop' regime where longer-tenured patients transition to intermittent treatment as disease management stabilizes. International expansion is identified as the primary revenue growth driver for 2026, leveraging a larger patient pool outside the US and favorable product labels. The company is maintaini ...